TLTFF Theralase Technologies Inc.

$TLTFF <----- 👀 Keep an eye (or two) on this one. Theralase (with their Ruvidar and Rutherin) has very good chances of being a real winner. I'm hoping for exponential returns on this one. $MRNA $IBRX $CGON $ENGN

One of those tiny biotech names where clinical data matters way more than the daily chart imo. Theralase Technologies. $TLTFF They're developing a light activated treatment for bladder cancer. Promising concept but still needs to prove itself in larger studies. Anyone here actually following the clinical results?

$TLTFF Why hasn’t anyone noted the number of insider buys made in August 2026? Just curious.

$TLTFF fwiw my ongoing chats with ChatGPT have yielded the following base case probability set: ruvidar regulatory approval: 65 - 75%- it’s not higher due to the significant drop off to 19% CR rate and its a single arm study. Commercially meaningful viability base case: 25 - 35% - this estimate concerns a commercially consequential outcome for shareholders (i.e. the challenges are many: there are already pre established treatment patterns, the ruvidar protocol requires additional equipment, workflow and training requirements and the company has not yet demonstrated it’s capable of securing a commercial partner on attractive terms). The Ferring collaboration has very high strategic importance. Without convincing cohort 2 evidence, commercial viability for ruvidar drops to 15-25%, with convincingly positive cohort 2 results commercial viability is 50-65%. Questions around partner/licensing are more about whether theralase has the right commercial capabilities and negotiating leverage.

$TLTFF Looks like SP is a bout to take off big time. Some seem worried here? peices will all soon fall in place….

$TLTFF A lot of penny stocks are nothing but pump'n dumps but this lil gem aint it. ✅ Add to your watch list. ✅ ---> $TLTFF

$TLTFF global one media didn’t help. Presenting at think equity conference isn’t going to help. Why? Because investors will look under the hood and see a woefully understaffed operation trying to prove it can run with the big dogs. No credible in-house BD expertise means who can even land a commercial licensing agreement if they get ruvidar approval? No head of clinical development means who the is doing all trial design groundwork for even one of the supposed 5 phase 0/1 Rutherin trials next year? No head of regulatory affairs and on and on… Oh and no willingness to tell us why when we pointedly ask for a better understanding of the company and how it credibly advances this potentially incredible scientific platform. Oh and don’t dare to request management and board accountability or changes because they will sue you and make your life hell. Yeah that’s a great sales pitch!

$TLTFF I recall Matt’s and Roger’s confidence at the outset of the year and how transformative it would be…fast forward 10 months. All cash raise holders significantly under water. Zero news on Ferring cohort 2. NDA pushed to Q4 and a subtle hint “thousands of pages” in the recent promo video that even Q4 could prove too optimistic. The execution risk with micro cap drug developers is almost always the science but with this company it’s the management. It’s run like a private company where unwelcome questions are ignored (or face litigation) and operational holes apparently remain low priorities despite enough cash to make important targeted hires now. Why not just tell us what’s in house and what’s outsourced? How are we to honestly believe in a company that offers complete unwillingness to speak about its regulatory affairs at this crucial moment? And clinical dev planning for future Rutherin trials ? And business development for licensing deals? Shareholders deserve more imo.